{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:29:33Z","timestamp":1785569373341,"version":"3.56.0"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The use of antivirals, corticosteroids, and IL-6 inhibitors has been recommended by the WHO to treat COVID-19. CP has also been considered for severe and critical cases. Clinical trials on CP have shown contradictory results, but an increasing number of patients, including immunocompromised ones, have shown benefits from this treatment. We reported two clinical cases of patients with prolonged COVID-19 infection and B-cell depletion who showed rapid clinical and virological recovery after the administration of CP. The first patient in this study was a 73-year-old female with a history of follicular non-Hodgkin lymphoma previously treated with bendamustine followed by maintenance therapy with rituximab. The second patient was a 68-year-old male with chronic obstructive pulmonary disease, bipolar disorder, alcoholic liver disease, and a history of mantellar non-Hodgkin lymphoma treated with rituximab and radiotherapy. After the administration of CP, both patients showed a resolution of symptoms, improvement of their clinical conditions, and a negative result of the nasopharyngeal swab test. The administration of CP might be effective in resolving symptoms and improving clinical and virological outcomes in patients with B-cell depletion and prolonged SARS-CoV2 infections.<\/jats:p>","DOI":"10.3390\/life13061266","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T16:10:53Z","timestamp":1685203853000},"page":"1266","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion"],"prefix":"10.3390","volume":"13","author":[{"given":"Luca","family":"Tomisti","sequence":"first","affiliation":[{"name":"ASL Toscana Nord-Ovest, Internal Medicine Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Angelotti","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Internal Medicine Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Lenzi","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amadori","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-662X","authenticated-orcid":false,"given":"Giovanni","family":"Sarteschi","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Porcu","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Pneumology Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lisa","family":"Capria","sequence":"additional","affiliation":[{"name":"UOC Virologia, Dipartimento di Medicina di Laboratorio, AOUP Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Bertacca","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, SSD Clinical Chemistry Analyses and Molecular Biology, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Lombardi","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, SSD Clinical Chemistry Analyses and Molecular Biology, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bianchini","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Internal Medicine Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Vincenti","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-7094","authenticated-orcid":false,"given":"Novella","family":"Cesta","sequence":"additional","affiliation":[{"name":"ASL Toscana Nord-Ovest, Infectious Diseases Department, Nuovo Ospedale Apuano, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 14). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int."},{"key":"ref_2","unstructured":"(2023, January 15). Therapeutics and COVID-19: Living Guideline, 13 January 2023. Available online: https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-therapeutics-2023.1."},{"key":"ref_3","unstructured":"(2020). Investigational COVID-19 Convalescent Plasma; Guidance for Industry, Food and Drug Administration."},{"key":"ref_4","first-page":"152","article-title":"Convalescent Plasma: New Evidence for an Old Therapeutic Tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2136246","DOI":"10.1001\/jamanetworkopen.2021.36246","article-title":"Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"4","author":"Menichetti","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent Plasma for Hospitalized Patients with COVID-19: An Open-Label, Randomized Controlled Trial","volume":"27","author":"Callum","year":"2021","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Heustess, A.M., Allard, M.A., Thompson, D.K., and Fasinu, P.S. (2021). Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. Pharmaceuticals, 14.","DOI":"10.3390\/ph14060520"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-Threatening COVID-19: A Randomized Clinical Trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e152740","DOI":"10.1172\/JCI152740","article-title":"A Multicenter Randomized Open-Label Clinical Trial for Convalescent Plasma in Patients Hospitalized with COVID-19 Pneumonia","volume":"131","author":"Torres","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e00200-21","DOI":"10.1128\/cmr.00200-21","article-title":"COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes","volume":"35","author":"Focosi","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1097\/HS9.0000000000000409","article-title":"The Emerging Role of Convalescent Plasma in the Treatment of COVID-19","volume":"4","author":"Psaltopoulou","year":"2020","journal-title":"HemaSphere"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102866","DOI":"10.1016\/j.transci.2020.102866","article-title":"First Case of Convalescent Plasma Transfusion in a Child with COVID-19-Associated Severe Aplastic Anemia","volume":"59","author":"Figlerowicz","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19","volume":"7","author":"Thompson","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/trf.16525","article-title":"Use of Convalescent Plasma in COVID-19 Patients with Immunosuppression","volume":"61","author":"Senefeld","year":"2021","journal-title":"Transfusion"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103071","DOI":"10.1016\/j.transci.2021.103071","article-title":"COVID-19 Neutralizing Antibody-Based Therapies in Humoral Immune Deficiencies: A Narrative Review","volume":"60","author":"Focosi","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"763412","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge","volume":"12","author":"Furlan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Grubovic Rastvorceva, R.M., Useini, S., Stevanovic, M., Demiri, I., Petkovic, E., Franchini, M., and Focosi, D. (2022). Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients\u2014An Open-Label Phase II Clinical Trial. Life, 12.","DOI":"10.3390\/life12101565"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1080\/10428194.2021.1872070","article-title":"Convalescent Hyperimmune Plasma for Chemo-Immunotherapy Induced Immunodeficiency in COVID-19 Patients with Hematological Malignancies","volume":"62","author":"Ferrari","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the Management of COVID-19 in Patients with Haematological Malignancies or Haematopoietic Cell Transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.7326\/M22-1079","article-title":"Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma","volume":"175","author":"Estcourt","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/S2665-9913(20)30270-8","article-title":"B-Cell Depletion with Rituximab in the COVID-19 Pandemic: Where Do We Stand?","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102554","DOI":"10.1016\/j.autrev.2020.102554","article-title":"Convalescent Plasma in Covid-19: Possible Mechanisms of Action","volume":"19","author":"Rojas","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clml.2020.06.012","article-title":"Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma","volume":"21","author":"Wright","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","first-page":"62","article-title":"Convalescent Plasma for Haematological Patients with SARS-CoV-2 Pneumonia and Severe Depletion of B-Cell Lymphocytes Following Anti-CD20 Therapy: A Single-Centre Experience and Review of the Literature","volume":"45","author":"Oliva","year":"2022","journal-title":"New Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103278","DOI":"10.1016\/j.transci.2021.103278","article-title":"Convalescent Plasma Therapy in B-Cell-Depleted and B-Cell Sufficient Patients with Life-Threatening COVID-19\u2014A Case Series","volume":"60","author":"Erber","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103075","DOI":"10.1016\/j.transci.2021.103075","article-title":"Convalescent Plasma Therapy for Severe Covid-19 in Patients with Hematological Malignancies","volume":"60","author":"Jeyaraman","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent Plasma Therapy for B-Cell\u2013Depleted Patients with Protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Belcari, G., Conti, A., Mazzoni, A., Lanza, M., Mazzetti, P., and Focosi, D. (2022). Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia. Life, 12.","DOI":"10.3390\/life12071098"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13223-021-00518-5","article-title":"Rapid Clinical Recovery of a SARS-CoV-2 Infected Common Variable Immunodeficiency Patient Following the Infusion of COVID-19 Convalescent Plasma","volume":"17","author":"Ribeiro","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103104","DOI":"10.1016\/j.transci.2021.103104","article-title":"Two Patients with Rituximab Associated Low Gammaglobulin Levels and Relapsed Covid-19 Infections Treated with Convalescent Plasma","volume":"60","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_34","unstructured":"US Food and Drug Administration (2023). Announces Evusheld Is not Currently Authorized for Emergency Use in the U.S., FDA."},{"key":"ref_35","unstructured":"Commissioner, O. (2023, April 20). Of the Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron."},{"key":"ref_36","unstructured":"Bloch, E.M., Focosi, D., Shoham, S., Senefeld, J., Baden, L.R., Tiberghien, P., Sullivan, D., Cohn, C., Henderson, J.P., and So-Osman, C. (2023). Guidance on the Use of Convalescent Plasma to Treat T Immunocompromised Patients with COVID-19. Clin. Infect. Dis., ciad066."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103326","DOI":"10.1016\/j.transci.2021.103326","article-title":"SARS-CoV-2 Antibody Changes in Patients Receiving COVID-19 Convalescent Plasma from Normal and Vaccinated Donors","volume":"61","author":"Leon","year":"2022","journal-title":"Transfus. Apher. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/bjh.18544","article-title":"Lower Anti-Spike Levels in B-Cell-Depleted Patients after Convalescent Plasma Transfusion Suggest the Need for Repeated Doses","volume":"200","author":"Focosi","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1266\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:43:17Z","timestamp":1760125397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/6\/1266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["life13061266"],"URL":"https:\/\/doi.org\/10.3390\/life13061266","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]}}}